ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0114

Incidence of Follow-Up Dual-Energy X-Ray Absorptiometry Scanner Error: A Contributor to Precision Error
Abstract Number: 0115

Improving Osteoporosis Screening in Men at a Resident-run Primary Care Clinic: A Quality Improvement Project
Abstract Number: 0116

The in Vitro 3D Fracture Gap Model: A Tool for Preclinical Testing
Abstract Number: 0117

Development of an In Vitro Trabecular Human Bone Model to Recapitulate Features of Glucocorticoid-induced Osteoporosis
Abstract Number: 0118

Indicators of Effectiveness After 6 Years of Follow-up in a Fracture Liaison Service
Abstract Number: 0119

Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes
Abstract Number: 0120

Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases
Abstract Number: 0121

Association of Low Bone Density with Need for Early Revision After Elective Joint Replacement for Osteoarthritis in Postmenopausal Women
Abstract Number: 0122

Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry
Abstract Number: 0123

Aromatase Inhibitor-Associated Bone Loss: Screening and Prevention
Abstract Number: 0124

Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience
Abstract Number: 0125

A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic
Abstract Number: 0126

Immunophenotyping of Peripheral Blood Highlights an Association of Dysregulated Lymphocytes with Patients with Glucocorticoid-induced Osteonecrosis
Abstract Number: 0127

Biochemical Algorithm to Identify Individuals with ALPL Variants Between Subjects with Persistent Hypophosphatasaemia
Abstract Number: 0128

Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].